Emerging Therapeutics for Ocular Surface Disease
暂无分享,去创建一个
[1] Jason K. Lee,et al. Omalizumab as single-dose therapy for vernal keratoconjunctivitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[2] L. Gentilucci,et al. DS‐70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs , 2018, British journal of pharmacology.
[3] Luis Santamaría,et al. [Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis]. , 2018, Revista alergia Mexico.
[4] R. Giuffrida,et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. , 2018, Arquivos brasileiros de oftalmologia.
[5] Hyun Soo Lee,et al. TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model , 2018, Ocular immunology and inflammation.
[6] Narendra P. Datti,et al. Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis , 2018, Journal of ophthalmic & vision research.
[7] C. Phan,et al. A Rapid Extraction Method to Quantify Drug Uptake in Contact Lenses , 2018, Translational vision science & technology.
[8] M. Cavet,et al. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial , 2018, Optometry and vision science : official publication of the American Academy of Optometry.
[9] S. Geschwindner,et al. Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile. , 2018, Journal of medicinal chemistry.
[10] J. Mehta,et al. A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. , 2018, Investigative Ophthalmology and Visual Science.
[11] H. DeCory,et al. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness , 2018, Current eye research.
[12] J. Oh,et al. Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis , 2017, Cornea.
[13] A. Lambiase,et al. Allergic conjunctivitis: current concepts on pathogenesis and management. , 2018, Journal of Biological Regulators and Homeostatic Agents.
[14] M. Ozaki,et al. Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment , 2017, Clinical ophthalmology.
[15] K. Kaarniranta,et al. Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.
[16] Qi Wan,et al. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis , 2017, Ophthalmic Research.
[17] F. Occasi,et al. Vernal keratoconjunctivitis treated with omalizumab: A case series , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[18] V. Rathi,et al. Role of Scleral Contact Lenses in Management of Coexisting Keratoconus and Stevens–Johnson Syndrome , 2017, Cornea.
[19] J. A. Gomes,et al. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. , 2017, Arquivos brasileiros de oftalmologia.
[20] M. Rohani,et al. Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study , 2017, Cornea.
[21] D. Freitas,et al. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. , 2017, Arquivos brasileiros de oftalmologia.
[22] Kyung-Mi Joo,et al. Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients , 2017, Scientific Reports.
[23] E. Takamura,et al. Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases. , 2016, Ophthalmology.
[24] V. Perez,et al. Emerging therapeutics for ocular surface disease , 2016, Current opinion in allergy and clinical immunology.
[25] M. Barzegar-Jalali,et al. Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate. , 2016, Advanced pharmaceutical bulletin.
[26] A. Concheiro,et al. Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. , 2016, Acta biomaterialia.
[27] Anuj Chauhan,et al. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. , 2016, Advances in colloid and interface science.
[28] Parvin Zakeri-Milani,et al. Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate , 2016, Iranian journal of basic medical sciences.
[29] E. Heffler,et al. Omalizumab Treatment of Vernal Keratoconjunctivitis. , 2016, JAMA ophthalmology.
[30] Hyun Soo Lee,et al. Topical Administration of β-1,3-Glucan to Modulate Allergic Conjunctivitis in a Murine Model. , 2016, Investigative ophthalmology & visual science.
[31] A. Adewale,et al. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model , 2015, Cornea.
[32] L. Pylkkänen,et al. A randomized phase I clinical study of cis‐urocanic acid eye drops in healthy adult subjects , 2015, Acta ophthalmologica.
[33] M. Baiula,et al. Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. , 2015, Inflammation & allergy drug targets.
[34] J. Ciolino,et al. Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials , 2014, Advances in Therapy.
[35] S. Vanzulli,et al. Restoring conjunctival tolerance by topical nuclear factor-κB inhibitors reduces preservative-facilitated allergic conjunctivitis in mice. , 2014, Investigative ophthalmology & visual science.
[36] P. Govoni,et al. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy , 2014, Drug design, development and therapy.
[37] V. Dimov,et al. Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis , 2014, Expert opinion on drug metabolism & toxicology.
[38] E. Turkoglu,et al. Comparative Evaluation of Olopatadine 0.01% Combined Fluorometholone 0.1% Treatment Versus Olopatadine 0.01% Combined Ketorolac 0.4% Treatment in Patients with Acute Seasonal Allergic Conjunctivitis , 2014, Current eye research.
[39] J. Wolffsohn,et al. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. , 2014, Ophthalmology.
[40] E. Meltzer,et al. An algorithm for the management of allergic conjunctivitis. , 2013, Allergy and asthma proceedings.
[41] P. Arkwright,et al. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. , 2013, Journal of AAPOS.
[42] S. McCabe,et al. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference , 2012, Clinical ophthalmology.
[43] R. Cardona,et al. Omalizumab. An option in vernal keratoconjunctivitis? , 2012, Allergologia et immunopathologia.
[44] Alex Hui,et al. Delivery of Ketotifen Fumarate by Commercial Contact Lens Materials , 2012, Optometry and Vision Science.
[45] Xinghuai Sun,et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. , 2012, Clinical therapeutics.
[46] H. Aono,et al. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[47] Francisco J. López,et al. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. , 2011, Investigative ophthalmology & visual science.
[48] S. Doan,et al. Omalizumab for severe atopic keratoconjunctivitis , 2010, BMJ Case Reports.
[49] L. Bielory,et al. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. , 2010, The Journal of allergy and clinical immunology.
[50] L. Bielory,et al. Emerging drugs for conjunctivitis , 2009, Expert opinion on emerging drugs.
[51] A. Karalezli,et al. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo‐controlled environmental trial , 2009, Acta ophthalmologica.
[52] M. Lemp,et al. Contact lenses and associated anterior segment disorders: dry eye disease, blepharitis, and allergy. , 2008, Immunology and allergy clinics of North America.
[53] L. Rosenwasser,et al. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge* , 2007, Current Medical Research and Opinion.
[54] S. Butrus,et al. Ocular allergy: diagnosis and treatment. , 2005, Ophthalmology clinics of North America.
[55] Y. Tekelioğlu,et al. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. , 2005, Clinical therapeutics.
[56] B. Lanier,et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model , 2004, Current medical research and opinion.
[57] V. Yaylalı,et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. , 2003, Acta ophthalmologica Scandinavica.
[58] G. Berdeaux,et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. , 2002, Clinical therapeutics.
[59] A. Epstein,et al. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. , 2002, Clinical therapeutics.
[60] M. Avunduk,et al. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. , 2000, Ophthalmology.
[61] G. Ciprandi,et al. Safety and Efficacy Comparison of Emedastine 0.05% Ophthalmic Solution Compared to Levocabastine 0.05% Ophthalmic Suspension in Pediatric Subjects with Allergic Conjunctivitis , 2000 .
[62] M. Abelson,et al. An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis , 2000 .
[63] A. J. Aguilar,et al. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. , 2000, Acta ophthalmologica Scandinavica. Supplement.
[64] S. L. Spector,et al. Conjunctivitis medicamentosa. , 1994, The Journal of allergy and clinical immunology.
[65] D. Easty,et al. Randomised Double-Masked Trial of Lodoxamide and Sodium Cromoglycate in Allergic Eye Disease , 1992, European journal of ophthalmology.
[66] M. Abelson,et al. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. , 1990, Archives of ophthalmology.